ArticleDiscover oncology2025
Development and validation of G2M signature-based prognostic model for stratifying colon cancer prognosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Kinase-based molecular subtyping and a prognostic risk model in colorectal cancer with functional validation of PLK4.Translational cancer research · 2026Article
- Mapping Genetic Modifiers of Polyp Formation inCells · 2026Article
- The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to develop a predictive model integrating G2M-related genes to enhance the prognostication of colon cancer.
methodsBased on the data from TCGA-COAD and GEO (GSE39582, GSE17536, GSE17537), we applied Cox regression with LASSO to create a colon cancer prognostic model and developed a Nomogram for survival prediction.
resultsOur initial univariate Cox regression analysis identified 15 common prognostic genes. Subsequent LASSO modeling refined this set to nine hub genes: BRIP1, CDCA2, HMGCR, HOXC10, PSMA5, PSMD6, SIX4, SLC12A2, and SPA17. Multi-omics analysis explored their protein expression, miRNA regulation, protein interactions, genomic variations, and drug sensitivity. The G2M prognostic model effectively categorized colon cancer patients into high- and low-risk groups, with the high-risk group showing significantly poorer overall survival. Further analysis of gene expression variances showed enrichment of extracellular matrix-related events. The G2M-based risk stratification correlated with the infiltration levels of immune cells, including Tregs, CD56dim natural killer cells, and M0-type macrophages. To aid clinical decision-making, we developed a Nomogram that developed the risk score with clinical parameters like tumor stage, age, and gender to forecast 1-, 3-, and 5-year survival rates.
conclusionsThis study presents an innovative prognostic model centered on the G2M, highlighting the indispensable role of G2M-related genes in colon cancer's clinical progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.